ICCC vs. ZURA, CLLS, PYXS, GNFT, ELDN, TARA, MDWD, CHRS, EPRX, and APLT
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Zura Bio (ZURA), Cellectis (CLLS), Pyxis Oncology (PYXS), GENFIT (GNFT), Eledon Pharmaceuticals (ELDN), Protara Therapeutics (TARA), MediWound (MDWD), Coherus Oncology (CHRS), Eupraxia Pharmaceuticals (EPRX), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.
ImmuCell vs. Its Competitors
ImmuCell (NASDAQ:ICCC) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 5.6% of ImmuCell shares are owned by company insiders. Comparatively, 22.1% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Zura Bio has a consensus target price of $11.60, indicating a potential upside of 248.35%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than ImmuCell.
ImmuCell has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.
In the previous week, Zura Bio had 3 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Zura Bio and 1 mentions for ImmuCell. Zura Bio's average media sentiment score of 0.39 beat ImmuCell's score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media.
ImmuCell has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.
ImmuCell has a net margin of 6.23% compared to Zura Bio's net margin of 0.00%. ImmuCell's return on equity of 6.25% beat Zura Bio's return on equity.
Summary
ImmuCell and Zura Bio tied by winning 8 of the 16 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
This page (NASDAQ:ICCC) was last updated on 10/22/2025 by MarketBeat.com Staff
Free ICCC Stock Alerts